HER4 及其胞质异构体与恶性黑色素瘤的无进展生存期相关。
HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.
机构信息
aDepartment of Clinical Biochemistry, University Hospital of Aarhus, Aarhus C bDepartment of Biomedical Sciences, The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark cLaboratory of Oncology and Experimental Surgery, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
Melanoma Res. 2014 Feb;24(1):88-91. doi: 10.1097/CMR.0000000000000040.
HER4 belongs to the epidermal growth factor (EGF) family. Mutations in HER4 are associated with malignant melanoma. This points to HER4 as an important receptor in malignant melanoma and also raises the question of whether the other receptors in the EGF system could be involved. RT-qPCR mRNA quantification was carried out of all four EGF receptors (EGFR, HER2, HER3, and HER4) and the HER4 cytoplasmic isoforms in lymph node metastases from patients with malignant melanoma. We related their expression to progression of the disease. HER4 expression was found to be an indicator of short progression-free survival (P=0.0340). Interestingly, of the two cytoplasmic splice variants of HER4, the association of CYT1 (P=0.0176) with progression-free survival was more pronounced than that for CYT2 (P=0.0458). Also, HER3 was associated with progression-free survival (P=0.0169), whereas no association was found for EGFR or HER2 with time to progression. Our results further emphasize the role of HER4 as an important oncogene in malignant melanoma and point to HER4 as a possible drug target in this disease.
HER4 属于表皮生长因子 (EGF) 家族。HER4 的突变与恶性黑色素瘤有关。这表明 HER4 是恶性黑色素瘤中一个重要的受体，也提出了 EGF 系统中的其他受体是否可能参与的问题。对恶性黑色素瘤患者淋巴结转移中的四个 EGF 受体（EGFR、HER2、HER3 和 HER4）和 HER4 细胞质异构体进行了 RT-qPCR mRNA 定量，并将其表达与疾病进展相关联。发现 HER4 的表达是无进展生存期（P=0.0340）较短的指标。有趣的是，在 HER4 的两种细胞质剪接变体中，与无进展生存期相关的 CYT1（P=0.0176）比 CYT2（P=0.0458）更明显。此外，HER3 与无进展生存期相关（P=0.0169），而 EGFR 或 HER2 与进展时间无关联。我们的结果进一步强调了 HER4 作为恶性黑色素瘤中一个重要致癌基因的作用，并指出 HER4 可能是该疾病的一个潜在药物靶点。
Zotero 插件